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Abstract: Colorectal cancer (CRC) is a common malignancy with a high mortality rate worldwide.
It is a complex, multifactorial disease that is strongly impacted by both hereditary and environmental
factors. The role of microbes (e.g., viruses) in the pathogenesis of CRC is poorly understood. In the
current study, we explored the status of high-risk human papillomaviruses (HPV) and Epstein–Barr
virus (EBV) in a well-defined CRC cohort using immunohistochemistry and polymerase chain reaction
assays. Our data showed that high-risk HPVs were common (~80%) and EBV had a low presence
(14–25%) in the CRC samples. The most common high-risk HPVs are HPV16, 31, 18, 51, 52 and 45
genotypes. The co-presence of high-risk HPV and EBV was observed in ~16% of the sample population
without any significant association with the clinicopathological variables. We conclude that high-risk
HPVs are very prevalent in CRC samples while EBV positivity is relatively low. The co-expression of
the two viruses was observed in a minority of cases and without any correlation with the studied
parameters. Further studies are necessary to confirm the clinical relevance and potential therapeutic
(preventive) effects of the observations reported herein.
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1. Introduction
Colorectal cancer (CRC) is the third most common cancer reported worldwide, and corresponds
to about 10% of all cancer cases [1]. It is considered to be second most common cause of mortality in
both developed and developing countries, affecting men and women equally [2].
CRC is a complex disease involving multiple factors including hereditary (family history and
genetic diseases such as familial adenomatous polyposis (FAP) and hereditary non-polyposis CRC
(Lynch) syndromes), (epi)genetic, lifestyle, environmental and viral factors [3].
Among viral factors, microbial–epithelial interactions are assumed to instigate oncogenic activity,
which could lead to the onset and development of CRC [3]. Viral infections by high-risk human
papillomaviruses (HPVs) and Epstein–Barr virus (EBV) have been linked with the initiation and
progression of several human carcinomas [4–6].
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HPV is a small epitheliotropic, non-enveloped, double-stranded DNA virus that can be sexually
transmitted. It infects the epidermal or mucosal epithelial cells, where HPVs can induce neoplastic
transformation (both benign and malignant) [7,8]. The multiplication of the virus occurs in cell nuclei
and is firmly linked to cell differentiation [9]. The HPV genome has eight open reading frames (ORFs)
and is divided into three functional elements (the early (E), and late (L)regions, and a long control
region (LCR)) [10]. The E) region is vital for processes like control of viral transcription as well as
replication and it encodes six proteins (E1, E2, E4, E5, E6 and E7) [11]. The L region takes part in virus
assembly by encoding the structural proteins (L1-L2) [10], whereas the high-risk HPV early proteins
(E5, E6 and E7) act as oncogenes, working closely together through molecular mechanisms involved in
the epithelial–mesenchymal transition (EMT) [11,12]. These proteins deregulate cell cycle progression,
immortalize epithelial cells, which leads to their neoplastic transformation in cooperation with other
oncogenes and/or oncoviruses [8,13,14]. Several studies have confirmed the etiological role of HPVs
in cervical [15] and head and neck carcinomas [16] while the role of HPVs in breast [17] and bladder
carcinomas [18] has been also proposed and reported.
On the other hand, EBV is a double-stranded DNA gamma-herpes virus, which infects 90%
of the adult population [2,19]. EBV causes infectious mononucleosis and various epithelial and
lymphoproliferative malignancies such as nasopharyngeal and gastric carcinoma as well as several
B-cell lymphomas and T-cell/NK lymphomas [19]. EBV genome is 184-kbp long and encodes over
85 genes including viral oncogenes such as six EBV-encoded nuclear antigens (EBNA1, -2, -3A, -3B,
-3C and -LP) and latent membrane proteins (LMP1, -2A, and -2B), as well as various noncoding RNAs
(EBERs and miRNAs) [2,20]. LMP1, oncogenic protein of EBV, is known to stimulate cell growth,
reduce apoptosis, promote cell motility, and angiogenesis [21,22]. During EBV infection, EBNA1 is the
only protein articulated in all forms of latency [23]. EBNA1 is considered as an oncoprotein and links
EBV infection to carcinogenesis [24].
Although previous studies have indicated the etiological role of HPV in rectal cancer [25–27],
the underlying mechanisms are still nascent. The role of EBV in rectal cancer is even less understood [28].
In the current study, we explored the co-presence of high-risk HPVs and EBV in a well-defined rectal
cancer cohort.
2. Results
2.1. Clinicopathological Characteristics of the Cohort
The clinicopathological characteristics of the cohort are summarized in Table 1. The study included
samples from 64 (60%) male and 42 (40%) female patients. The mean age of the patients was 65 years
(range, 41–86 years) and the vast majority of specimens were taken from the rectum (102 cases, 96%).
The remaining four samples were from the sigmoid colon and other parts of the large bowel (Table 1).
Table 1. The clinicopathological characteristics of the cohort.
Variable Total (%)
†
n = 106
Age (mean ± SD) 65 ± 8 yrs
Tumor grade
Grade 1 1 (1)
Grade 2 65 (62)
Grade 3 39 (37)
Tumor stage *
Stage I 22 (21)
Stage II 23 (22)
Stage III 54 (52)
Stage IV 5 (5)
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Table 1. Cont.
Variable Total (%)
†
n = 106
Sex
Male 64 (60)
Female 42 (40)
Tumor origin
Rectum 102 (96)
Sigmoid colon 2 (2)
Other parts of colon 2 (2)
† Numbers may not add up to the total number of subjects because of some missing values. * The staging was
according to the American Joint Committee on Cancer (AJCC) TNM system (8th edition). SD = Standard deviation.
All tumors were histologically adenocarcinomas. The majority of cancers were grade two
(moderately differentiated) (65 cases, 62%) (Figure 1A,B) while 39 cases (37%) were grade three (poorly
differentiated).
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Figure 1. (A,B) Hematoxylin and eosin (H&E) slides of a case of moderately differentiated rectal 
carcinoma with a strong (3+) intensity of E6 protein by immunohistochemistry (C,D) and moderate 
(2+) expression of LMP1 protein (E,F) (Red arrows indicate positive cancer cells; (A,C,E) images 4×, 
(B,D) and (F) images, 10× magnification). 
Only one case was well-differentiated (grade 1) rectal adenocarcinoma (Table 1). Notably, 
twenty-one cases (20%) had been previously treated with neoadjuvant chemotherapy or combined 
chemo- and radiotherapy. None of the cases had received targeted therapies (e.g., anti-EGFR, anti-
angiogenic or immune checkpoint inhibitors) prior to the surgery. 
2.2. The Status of High-Risk HPV Subtypes and EBV by PCR 
The PCR data for HPVs and EBV and their association with the clinicopathological parameters 
are summarized in Table 2.   
Figure 1. (A,B) Hematoxylin and eosin (H&E) slides of a case of moderately differentiated rectal
carcinoma with a strong (3+) intensity of E6 protein by immunohistochemistry (C,D) and moderate
(2+) expression of LMP1 protein (E,F) (Red arrows indicate positive cancer cells; (A,C,E) images 4×,
(B,D,F) images, 10×magnification).
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Only one case was well-differentiated (grade 1) rectal adenocarcinoma (Table 1). Notably,
twenty-one cases (20%) had been previously treated with neoadjuvant chemotherapy or combined
chemo- and radiotherapy. None of the cases had received targeted therapies (e.g., anti-EGFR,
anti-angiogenic or immune checkpoint inhibitors) prior to the surgery.
2.2. The Status of High-Risk HPV Subtypes and EBV by PCR
The PCR data for HPVs and EBV and their association with the clinicopathological parameters
are summarized in Table 2.
Table 2. The relationship between human papillomaviruses (HPV) and Epstein–Barr virus (EBV) status
by PCR and clinicopathological variables.
Variable
HPV (PCR) EBV (PCR)
(−)
n = 8 (%)
(+)
n = 98 (%)
(−)
n = 80 (%)
(+)
n = 26 (%)
Tumor grade
Grade 1 0 (0) 1 (1) 1 (1) 0 (0)
Grade 2 6 (75) 59 (61) 48 (61) 17 (65)
Grade 3 2 (25) 37 (38) 30 (38) 9 (35)
p-value 0.72 0.80
Tumor stage *
Stage I 1 (12) 20 (21) 15 (19) 6 (23)
Stage II 2 (25) 22 (23) 19 (24) 5 (19)
Stage III 4 (50) 49 (51) 40 (51) 13 (50)
Stage IV 1 (12) 5 (5) 4 (5) 2 (8)
p-value 0.81 0.83
Sex
Male 4 (50) 60 (61) 46 (58) 18 (69)
Female 4 (50) 38 (39) 34 (42) 8 (31)
p-value 0.53 0.29
Tumor origin
Rectum 0 (0) 94 (96) 77 (96) 25 (96)
Sigmoid 0 (0) 2 (2) 2 (3) 0 (0)
Other parts of colon 0 (0) 2 (2) 1 (1) 1 (4)
p-value 0.84 0.51
HPV (+) 25 (96)
p-value 0.41
* The staging was according to the American Joint Committee on Cancer (AJCC) TNM system (8th edition).
PCR = polymerase chain reaction; HPV = human papillomavirus; EBV = Epstein–Barr virus.
The most commonly found high-risk HPVs in the entire cohort (n = 106) were HPV16 (53%)
followed by HPV31 (51%), HPV18 (50%), HPV51 (46%), HPV52 (39%), HPV45 (39%), HPV35 (26%),
HPV56 (9%) and HPV39 (0.9%).
Four common high-risk HPVs (16, 18, 31 and 35) were found in 82% of the cases, while twenty-five
cases (22.6%) were co-infected with both HPV16 and 18. Notably, HPV16-/HPV18+ phenotype was
significantly higher (75%) in males compared with HPV16+/HPV18- phenotype (48%) (p = 0.035).
On the other hand, 15/106 patients (14.1%) were positive for EBNA1 alone and 26/106 (24.5%)
were positive for the LMP1 gene of EBV; 15/106 (14.1%) of the cases were positive for both (EBNA1 and
LMP1) sequences. Although all the EBNA1-positive tumors were LMP1-positive tumors, the same did
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not hold for LMP1-positive tumors. Only 16% (17/106) of the colorectal cases were positive for both
high-risk HPVs and EBV.
Among the rectal cancer cases (n = 102), the four most common high-risk HPVs (16, 18, 31 and 35)
were present in 83/102 (81%) of the cases, while twenty-three cases (22.5%) were co-infected with both
HPV16 and 18 (Figure 2).Pathogens 2020, 9, x OR PEER REVIEW 6 of 15 
 
 
Figure 2. The distribution of each high-risk HPV subtype by PCR according to the frequency in the 
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Figure 2. The distribution of each high-risk PV subtype by PCR according to the frequency in the
rectal cancer (RC) cohort (n = 102).
Moreover, the rectal cancers were co-infected with more than one type of HPV in 74 out of
102 samples (72.5%). Figure 3 shows the most common co-infections of rectal cancer samples with
HPV16 and other high-risk HPV subtypes. Three or more co-infections were seen in 58/102 rectal
cancer samples (57%), fourteen cases (13.6%) had three HPV co-infections, 18 cases (17.5%) had
four co-infections, 11 cases (10.7%) had five co-infections, 12 cases (11.7%) had six co-infections
while three cases (2.9%) had seven high-risk HPV co-infections (Supplementary Table S1). The most
commonly expressed combinations were HPV16/18/51 (11/102, 10.8%) followed by HPV16/18/31 in
10/102 (9.8%) cases.
EBNA1 and LMP1 were individually present in 15/102 (14%) and 25/102 (24%) of the cases,
respectively; 15/102 (14%) of the cases were positive for both (EBNA1 and LMP1) sequences.
Although all the EBNA1-positive tumors were LMP1-positive tumors, the same did not hold for
LMP1-positive tumors.
To calculate the number of EBV cases, EBNA1 and LMP1 positive samples were taken together,
which came to a total of 26 cases. The co-presence of EBV (EBNA1 and LMP1) and high-risk HPVs was
detected in 16% (16/102) of the rectal cases (Table 3). In addition, a significant correlation between EBV
and various HPV types (HPV16 (p = 0.02), HPV18 (p = 0.03), HPV35 (p = 0.03), HPV52 (p = 0.03) and
HPV56 (p = 0.003) was found in the rectal cancer samples (χ2 test with Yates correction) (Table 3).
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Figure 3. The distribution of co-infection of HPV16 with other high-risk HPV subtypes in rectal cancer.
The most commonly co-infected subtype was HPV16/51 (31/102; 30.4%) followed by HPV16/31 (29/102;
28.4%), HPV16/18 and HPV16/35 (23/102; 22.5% each). Since, HPV33 and HPV58 were not present in
the cohort, there was no co-expression for HPV16 with these subtypes.
Table 3. The prevalence of high-risk HPV types and their relationship to EBV status in the rectal cancer
ohort (n = 102). Significant p-values are labeled with an asterisk.
Samples No. f Cases
High-Risk HPV Types
16 18 31 33 35 39 45 51 52 56 58
EBV (+) 26 18 17 15 0 11 0 7 16 7 6 0
EBV (−) 76 30 30 37 0 14 0 30 30 6 2 0
Total 102 48 47 52 0 25 0 37 46 13 8 0
p-value 0.02 * 0.03 * 0.57 N/A 0.03 * N/A 0.36 0.08 0.03 * 0.003 ** N/A
2.3. Immunohistochemical Expression of E6 (HPVs) and LMP1 (EBV)
The immunohistochemical (IHC) data for HPV and EBV and their relationship to the
clinicopathological parameters are summarized in Table 4.
Interpretable results by IHC were obtained for 58 cases of HPVs. Forty-five cases (77.5%) were
positive for E6 above the threshold of 1% of positive cancer cells; in contrast, LMP1 of EBV expression
was found in 11% of the cases (7/63) (Table 4). Four out of seven LMP1-positive cases also co-expressed
E6 of HPV (Figure 1C–F). When positive, both E6 of HPV and LMP1 of EBV expression was diffused
(>50% cancer cells were positive) in the majority of the cases. Notably, adjacent normal mucosa was
devoid of E6 while LMP1 expression was occasionally seen in tumor-infiltrating lymphocytes (TIL)
and lymphatic aggregates within the tumor and adjacent structures.
Positive samples for E6 of HPV showed a statistically significant association with cancers of rectal
origin (p = 0.024). In addition, LMP1 of EBV positive samples by IHC seemed to be associated with
grade 2 adenocarcinomas (p = 0.035) (Table 4).
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PCR and IHC data were in good concordance for HPV analysis while discrepant data were
observed in EBV assessment; however, the inter-reliability rating between PCR and IHC was fair
(Kappa = 0.31; p = 0.005).
Table 4. The relationship between HPV and EBV expressions by immunohistochemical (IHC) and
clinicopathological variables.
Variable
HPV (IHC) EBV (IHC)
(−)
n = 13 (%)
(+)
n = 45 (%)
(−)
n = 56 (%)
(+)
n = 7 (%)
Age (years)
p-value 0.44 0.76
Tumor grade
Grade 1 0 (0) 0 (0) 0 (0) 0 (0)
Grade 2 8 (62) 27 (61) 33 (60) 7(100)
Grade 3 5 (38) 17 (39) 22 (40) 0 (0)
p-value 0.92 0.035
Tumor stage *
Stage I 3 (25) 7 (16) 10 (18) 0 (0)
Stage II 1 (8) 6 (14) 8 (15) 1 (14)
Stage III 6 (50) 28 (64) 32 (58) 6 (86)
Stage IV 2 (17) 3 (6) 5 (9) 0 (0)
p-value 0.31 0.38
Sex
Male 6 (50) 30 (68) 34 (62) 4 (57)
Female 6 (50) 14 (32) 21 (38) 3 (43)
p-value 0.32 0.78
Tumor origin
Rectum 10 (83) 42 (95) 52 (95) 6 (86)
Sigmoid 0 (0) 2 (5) 2 (3) 0 (0)
Other parts of colon 2 (17) 0 (0) 1 (2) 1 (14)
p-value 0.024 0.19
HPV (+) 4 (57)
p-value 0.89
* The staging was according to the American Joint Committee on Cancer (AJCC) TNM system (8th edition).
IHC = immunohistochemistry; HPV = human papillomavirus; EBV = Epstein–Barr virus.
3. Discussion
There are various types of HPV-associated cancers including cervical, vulvar, vaginal, penile,
rectal, anal and oropharyngeal cancer [29]. From a clinical and therapeutic point of view, exploring
HPV status in cancers could be highly relevant due to the prophylactic vaccines that have been shown
to be effective in preventing common HPV-associated cancers such as cervical cancer [29].
In this investigation we explored for the first time, the co-presence of high-risk HPVs and EBV in
human CRC in the Bosnian population; our study found a high prevalence of high-risk HPVs and
a low positivity of EBV in CRC samples. The most frequent HPV types in our cohort are 16, 31, 18,
51, 52, and 45. This is also, to the best of our knowledge, the first report regarding the distribution of
high-risk HPVs in CRC samples from Bosnia. Our data are similar to those reported for a large cohort
of cervical cancer patients by de Sanjose et al. [30] and from Bosnian cervical cancer patients [31–33].
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Among our HPV-positive rectal cases, HPV16 and HPV18 were the most prevalent genotypes (~50%),
which is in line with the HPV distribution in cervical cancer samples that were previously reported in
the Bosnian population [31–33]. In Polish CRC samples, HPV16 and 18 were also the most common
HPV serotypes (~60%) [34]. Another study done on Italian CRC patients revealed HPV in 33% of the
cases [35]. A meta-analysis study based on the European population showed that HPV18 was present
in 47% of CRC cases [36]. The overall HPV16+/18+ prevalence in our study was ~23%, which is similar
to the findings in cervical cancer samples from the Croatian population (21%) [37]. HPVs 16, 31 and 18
were also the most common high-risk HPVs in cervical cancer samples in Serbian women [38]. In our
study, the other expressed HPV-types included HPV−45, −51 and −52, which have been previously
reported in cervical cancer in Bosnia [33]. Moreover, HPV45 has been previously found in colorectal
cancer [25,39]. Studies done in the USA and Iran identified HPV-51 as the most frequent HPV subtype
in colorectal cancer [39,40].
The highest reported EBV-positivity in CRC was up to 46%, with the majority of the studies
reporting EBV positivity of 20–40% [19,28,41,42]. Our study indicated the individual presence of
EBNA1 and LMP1 genes of EBV in 14% and 25% of the samples, respectively. EBV consists of
two strains, B95–8 (EBV type 1) and AG876 (EBV type 2), which also known as type A and type
B, respectively [43]. These EBV variants are differentiated based upon genetic differences in EBNA
sequences [43], and discrepancies in EBV variants have previously been described in breast cancer
samples [44]. This can be explained by the different roles of EBNA and LMP genes. In general, EBNA1
acts as a transcriptional activator that binds to the FR element, thereby enhancing the expression
of the viral Cp promoter and LMP genes. This in turn leads to transcriptional activation of viral
LMP genes (LMP-1 and -2) promoting cellular proliferation [45–47]. During latency 0, no EBNA
protein is expressed, while only one EBNA (EBNA1) is expressed during latency I and II, and during
latency III, all six EBNAs are expressed [48–50]. Further, the co-presence of both EBNA1 and LMP1
in our cohort can be explained by the fact that in EBV-infected cells, in the latent phase, EBNA1 and
LMP1 are expressed in a cancer-specific manner [51]. Thus, the most restricted pattern of viral latent
gene expression (latency 1: EBNA1 and EBERs) is expressed in Burkitt lymphomas [51,52] while the
unrestricted pattern of viral gene expression (latency II and III: EBNA1, LMPs and EBERs) is expressed
in Hodgkin lymphomas, diffused large B cell lymphomas and EBV-positive gastric and nasopharyngeal
carcinomas [51,52]. Regardless of the latency pattern, virtually all EBV-associated malignancies express
EBNA-1 and EBERs [52]. In addition, the functional variance can be explained by the genetic diversity
of the LMP-1 gene, which shows a higher degree of polymorphisms than most EBV genes [53,54].
Ten main LMP1 variants (China 1, China 2, China 3, NC (North Carolina), Mediterranean+ (Med+),
Med-, GD1, SEA 1, and SEA 2) have been defined in different regions and diseases [55–57].
Karpinski et al. reported that 19% of the CRC cases from Poland were EBV positive [58]. In an
Italian CRC cohort, the EBV-positivity rate ranged from 3–29% according to RT-PCR and sequencing
assays [59]. Another study in Italy did not find any significant involvement of any oncogenic virus
(HPV, HTLV, HHV-8, JCV, BKV and Merkel cell polyomavirus), except for EBV (52%) [60]. However,
a Czechoslovakian study failed to detect any oncogenic virus (EBV, HPV and CMV) in adenocarcinoma
of the colon [61]. A Chinese cohort of colorectal carcinomas was reported to be EBV positive (LMP1) in
27% of the samples [62].
The combined oncogenic effects of viral infections have been recognized as potential oncogenic
drivers in various cancers [6]. Oncoviruses can lead to the onset and progression of cancer via commonly
shared pathways including WNT/β-catenin, JAK/STAT/SRC, PI3k/Akt/mTOR, and/or RAS/MEK/ERK
signaling pathways [6,8,14,41]. A study conducted by Guidry and Scott [63] showed that co-infection
by HPV and EBV enhances EBV persistence either via latency or increased viral replication or by
aggregating HPV oncogene expression. Our group has previously demonstrated that oncoproteins of
EBV and high-risk HPVs can interact during the onset of human carcinomas, and subsequently result in
metastasis progression via epithelial–mesenchymal transition [14]. Epithelial differentiation stimulates
both the productive and lytic phases of HPV and EBV, respectively; high-risk HPV stabilizes the
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EBV genome and induces EBV lytic reactivation in differentiating epithelial cells, which suggests that
co-infection with HPV may increase EBV-mediated pathogenesis of CRC [64]. Additionally, HPV and
EBV may work together to promote the proliferation of cultured cervical [65] and prostate cells [66],
suggesting the same for colorectal epithelial cells. In our study, co-expression of EBV and HPV was
seen in only ~16% of CRCs. This co-expression was not associated with any noted clinicopathological
parameters. The lack of any association may be due to the relatively small sample size as well as low
EBV positivity in the cohort.
4. Materials and Methods
4.1. Sample Collection and DNA Extraction
The study included 106 formalin-fixed paraffin-embedded (FFPE) tissue samples that were
diagnosed in 2010–2017 at the Department of Pathology, University Clinical Center Sarajevo, Bosnia and
Herzegovina. For the study, all cases were de-identified and patients’ information anonymized.
The study was conducted based on the IBC approval of the local research committee (#IBC-2019/005).
Prior to molecular assays, all cases were re-reviewed by board-certified pathologists (F.S. and S.V.)
to confirm the diagnosis and select appropriate FFPEs for tissue microarray, immunohistochemistry
and PCR assays.
DNA was extracted from FFPE tissue samples using the Thermo Scientific GeneJET FFPE DNA
Purification Kit according to the manufacturer’s instructions (ThermoFisher Scientific, USA). Briefly,
FFPE sections were subjected to enzymatic digestion using 200 µL of digestion buffer. After digestion,
20 µL Proteinase K solution was added to lyse and release genomic DNA, which was de-crosslinked by
heat incubation (90 ◦C) for 40 min. The obtained solution was further centrifuged and the supernatant
containing DNA was mixed with 200 µL binding buffer. After addition of ethanol (96%), the lysate was
loaded onto the purification column and the adsorbed DNA was subjected to washing (wash Buffers 1
and 2) to eliminate contaminants. DNA was eluted with 60µL elution buffer.
4.2. EBV and HPV Detection by PCR
Twenty-five nanograms of purified genomic DNA from each sample was analyzed for
HPV and EBV by polymerase chain reaction (PCR) as previously described [67] using specific
primers for HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56 and 58 as well as EBNA1
(Forward Primer: 5′-GAGCGGGGAGATAATGTACA-3′ and Reverse Primer: 5′-TAAAAGATGGC
CGGACAAGG-3′) and LMP1 (Forward Primer: 5′-TTGGAGATTCTCTGGCGACT-3′ and Reverse
Primer: 5′-AGTCATCGTGGTGGTGTTCA-3′) of EBV. GAPDH primers (Forward Primer:
5′-GAAGGC-CATGCCAGTGAGCT-3′ and Reverse Primer: 5′ CCGGGAAACTGTGGCGTGAT-3′)
were used as internal control. All the primers and analyses were performed as previously described [68].
PCR was performed using the Invitrogen Platinum II Hot-Start Green PCR Master Mix (2X)
(ThermoFisher Scientific, Waltham, MA, USA). Briefly, HPV gene was amplified for an initial
denaturation at 94 ◦C for 2 min followed by 40 cycles of 94 ◦C for 30 s, annealing at temperatures
ranging from 50 to 62 ◦C for 30 s depending on each primer’s melting temperature as previously
described [68], and 72 ◦C for 30 s. In parallel, EBNA1 and LMP1 genes were amplified for an initial
denaturation at 94 ◦C for 2 min followed by 40 cycles of 94 ◦C for 30 s, 61 ◦C for 30 s, and 72 ◦C for 30 s.
The samples were finally incubated for 10 min at 72 ◦C for a final extension. The PCR product from
each exon was resolved using 1.5% agarose gel electrophoresis.
4.3. Tissue Microarray (TMA)
Tissue microarray was constructed as described previously by our group [17]. Briefly, cancer
samples and controls were embedded into a virgin paraffin TMA block using a manual tissue arrayer
(Beecher Instruments, Silver Spring, MD, USA).
Pathogens 2020, 9, 452 10 of 14
Following the sampling of two TMA cores of 1.0 mm in diameter, sections of 4µm were cut and
stained with hematoxylin and eosin (H&E) on the initial slides to verify the histopathological diagnosis.
Next, slides of completed blocks were used for immunohistochemical assays.
4.4. Immunohistochemistry (IHC)
Immunohistochemical assays for E6 (HPV) and LMP1 (EBV) expression were performed using
procedures as previously described [17]. For TMA construction, each slide was deparaffinized in
graded alcohol, rehydrated and boiled (microwave) in 10 mM citrate sodium solution (pH 6.0) for
10 min. Endogenous peroxidase activity within the rehydrated tissue was blocked with a solution
of 3% hydrogen peroxide in methanol for 10 min at room temperature. TMA slides were further
incubated for 35 min at 37 ◦C with primary monoclonal antibodies for E6 (clones 1–4 and C1P5,
Dako Agilent, Carpinteria, CA, USA and Calbiochem, Canada) and LMP1 (clone CS1–4, Abcam) using
a fully automated immunostainer (Ventana Medical System, Tucson, AZ). The fully automated Ventana
Medical System uses an indirect biotin–avidin system with a universal biotinylated immunoglobulin
secondary antibody. The slides were counterstained with hematoxylin prior to mounting. The staining
procedures were completed according to the manufacturer’s recommendations. Negative controls
were obtained by omitting specific primary antibodies for E6 and LMP1 as well as specific blocking
peptides from Santa Cruz Biotechnology.
The tumors were considered positive for E6 and LMP1 if cancer cells exhibited positivity ≥1% of
the cells [69]. In the case of LMP1 protein expression, we also evaluated the presence of viral infection
in tumor-infiltrating lymphocytes and stromal cells [69,70].
4.5. Statistical Analysis
The Spearman Correlation Rank test was used to assess the significance of HPV and EBV
associations. The Kolmogorov–Smirnov test and histograms were used to assess normal distribution.
Categorical variables were compared using Chi square and Kruskal–Wallis tests while Cramer’s V test
was used to assess a possible association between nominal and ordinal variables in asymmetric tables.
HPV and EBV IHC status were included as the dependent variables in a multiple regression analysis
to test the relationship with other independent variables such as age, gender, tumor location, stage,
and grade. The values for missing samples were excluded from the regression analysis. Cohen’s kappa
coefficient was used to assess inter-rater reliability for categorical variables. The results were considered
statistically significant if p-values were ≤0.05 in two-tailed tests. All the statistical analyses were
performed using IBM Statistical Package for the Social Sciences (version 25).
5. Conclusions
We conclude that high-risk HPVs are prevalent in CRC samples while EBV positivity is relatively
low. The co-presence of the two viruses was observed in a minority of the cases and without any
correlation with the studied parameters. Further studies are necessary to confirm the clinical and
preventive relevance of the observed findings.
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